重组人血管内皮抑制素联合含铂方案一线治疗晚期非小细胞肺癌的临床疗效  

Efficacy of recombinant human vascular endostatin in combination with platinum-based regimen as the first-line therapy for patients with advanced non-small cell lung cancer

作　　者：王慧娟[1] 王启鸣[1] 张国伟[1] 朱辉[1] 李鹏[1] 闫相涛[1] 戚冠斌[1] 马智勇[1] 

机构地区：[1]河南省肿瘤医院内科,郑州450003

出　　处：《肿瘤》2011年第3期264-268,共5页Tumor

摘　　要：目的:研究重组人血管内皮抑制素联合含铂方案一线治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效。方法:2007年5月-2009年4月共40例晚期NSCLC患者接受重组人血管内皮抑制素联合标准含铂方案一线治疗,共化疗4～6个周期。每一个化疗周期第1～14天给予重组人血管内皮抑制素15mg静脉滴注。观察近期疗效、无进展生存期和总生存期,并分析与其相关的临床病理因素。结果:37例患者可评价近期疗效,客观缓解率为29.7%,疾病控制率为81.8%。全部患者的中位无进展生存期为11.1个月,中位总生存期为23.0个月。亚组分析结果显示,病理类型(风险比=0.366,95%可信区间为0.160～0.840,P=0.018)和临床分期(风险比=0.405,95%可信区间为0.174～0.942,P=0.036)与无进展生存期相关;性别、年龄、病理类型和临床分期均与总生存期无明显相关性。结论:重组人血管内皮抑制素联合标准含铂方案一线治疗晚期NSCLC,可延长患者的无进展生存期和总生存期。Objective：To evaluate the short-term effect and the survival of patients with advanced non-small cell lung cancer（NSCLC） after receiving recombinant human vascular endostatin（Endostar） therapy in combination with standard platinum-based regimen.Methods：Forty eligible patients were recruited from May 2007 to April 2009,and they received Endostar（15 mg/d,d 1 to d 14,per 3 weeks a cycle） plus platinum-based regimen（per 3 weeks a cycle） for 4-6 cycles.The objective response rate（ORR）,disease control rate（DCR）,progression-free survival（PFS） and the overall survival（OS） were evaluated.Subgroup analysis was based on the clinicopathological features.Results：Of 40 patients,37 could be evaluated for short-term response.The ORR was 29.7%,and the DCR was 81.8%;the median PFS was 11.1 months,and the median OS was 23.0 months.Subgroup analysis showed that PFS was associated with histology（hazard ratio = 0.366;95% confidence interval：0.160-0.840;P = 0.018） and the clinical stage（hazard ratio = 0.405;95% confidence interval：0.174-0.942;P = 0.036）.The gender,age,histology and the clinical stage were not associated with OS.Conclusion：Treatment of Endostar in combination with standard platinum-based regimen may prolong the PFS and OS of patients with advanced NSCLC.

关 键 词：癌 非小细胞肺 重组人血管内皮抑制素 抗肿瘤联合化疗方案 无进展生存 

分 类 号：R734.2[医药卫生—肿瘤]